跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
GLIAVIS MR TABLET 30MG - HSA Drug Approval Details
Approvals
/
HSA
/
GLIAVIS MR TABLET 30MG
Approved
THERAPEUTIC
GLIAVIS MR TABLET 30MG
BALKANPHARMA-DUPNITSA AD
🇸🇬 Health Sciences Authority
Approval Date
May 8, 2018
Approval ID
3339fdf5f1659fe7
Company
BALKANPHARMA-DUPNITSA AD
Type
Therapeutic
Approval Details
Approval Id
3339fdf5f1659fe7
Drug Name
GLIAVIS MR TABLET 30MG
Product Name
GLIAVIS MR TABLET 30MG
Approval Number
SIN15478P
Approval Date
2018-05-08
Registrant
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Licence Holder
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Drug Type
Therapeutic
Forensic Classification
Prescription Only
Dosage Form
TABLET, EXTENDED RELEASE
Route Of Administration
ORAL
Atc Code
A10BB09
Atc Item Name
gliclazide
Pharma Manufacturer Name
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Company Detail Path
/organization/teva-pharmaceutical-investments-singapore-pte-ltd
Active Ingredients
Gliclazide
30 mg
Gliclazide
30 mg
Approved
Quick Info
Agency
HSA
Country
🇸🇬
Approval Date
May 8, 2018
Approval ID
3339fdf5f1659fe7
Type
Therapeutic
Back to HSA Approvals